Clinical Trial Update: A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase [Phase 3]

View source ↗

Summary

Phase 3 trial of pegylated interferon alfa-2a with lamivudine or entecavir versus untreated control in children with immune-tolerant, HBeAg-positive chronic hep…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• ENTECAVIR (ENTECAVIR)
• Lamivudine (lamivudine)
• Pegylated interferon alfa-2a (Peginterferon alfa-2a)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Pediatric Immuno-Tolerant Chronic Hepatitis B | Phase 3 | Status: COMPLETED | Results posted: 2020-08-24